Alicia Morgans, MD

Alicia Morgans, MD, MPH Genitourinary Medical Oncologist, Medical Director of Survivorship Program at Dana-Farber Cancer Institute, Boston, Massachusetts. She is a clinician and physician investigator specializing in investigating complications of systemic therapy for prostate cancer survivors. She has expertise in clinical trials and patient-reported outcome measures, and as well as incorporating patient preferences and beliefs into clinical decision making.

Dr. Charles J. Ryan, MD

Charles J. Ryan, MD is the President and Chief Executive Officer of The Prostate Cancer Foundation (PCF), the world’s leading philanthropic organization dedicated to funding life-saving prostate cancer research. Charles (Chuck) J. Ryan is an internationally recognized genitourinary (GU) oncologist with expertise in the biology and treatment of advanced prostate cancer. Dr. Ryan joins the PCF from the University of Minnesota, Minneapolis, where he served as Director of the Hematology, Oncology, and Transplantation Division in the Department of Medicine. He also served as Associate Director for Clinical Research in the Masonic Cancer Center and held the B.J. Kennedy Chair in Clinical Medical Oncology. Prior to moving to the University of Minnesota, he was on the faculty of the University of California, San Francisco, where he served as Program Leader for Genitourinary Medical Oncology and held the title of Thomas Perkins Distinguished Professor in Cancer Research. Dr. Ryan earned his medical degree from the University of Wisconsin Medical School and a BA in Philosophy, magna cum laude from Marquette University. He trained at the University of Wisconsin Hospital and Clinics, serving as Chief Resident, and at Memorial Sloan Kettering Cancer Center in New York.

Clinician voices sharing insights View all
Physician-Scientist Review Articles
State of the Evidence Review Articles
Written by William Whitlow, Prostate Cancer Survivor
October 27, 2021
Some African American men are reluctant to have their prostate checked although they are at higher risk.  But it’s critical. Had I not been getting my PSA checked since I was 40, I wouldn’t have caught the disease early enough and my quality of life could have suffered …or worse.
Written by Christopher J.D. Wallis, MD, PhD, and Zachary Klaassen, MD MSc
April 21, 2021
In 2021, there will be an estimated 9,470 new cases of testicular cancer in the United States with an estimated 440 testis cancer-related deaths.1 Importantly, the vast majority of men with testis cancer, even in advanced stages, are cured as a result of the success of high dose chemotherapy regimens that are tolerated by this typically young and healthy patient population. Given both the relatively young age at diagnosis and overall high survival rates, there has been a much needed and welcome focus on survivorship for testicular cancer patients.

Conference Coverage
Conference Highlights Written by Physician-Scientist
Presented by Alicia K. Morgans, MD, MPH
Dr. Morgans presented initial results of an international survey of patients with prostate cancer. The goal of this survey was to map patient experiences, expectations, and attitudes, and to identify challenges and unmet needs in diagnosis, therapy patterns, care teams, quality of life (QoL), patient organizations and resources.
Presented by Ray Allen, Deputy Chair, The Consumer Advisory Panel (CAP), ANZUP
The 2021 ANZUP Annual Scientific Meeting included a presentation by Ray Allen on the Consumer Advisory Panel (CAP) group. This group is composed of individuals with personal or indirect personal experiences with cancer who contribute expertise with a diverse disease-related experience.
Presented by Quoc-Dien Trinh, MD
In the Society of Urologic Oncology (SUO) plenary session held at the American Urological Association (AUA) Virtual Annual Meeting this afternoon, Dr. Quoc-Dien Trinh addressed the question of how the COVID-19 pandemic has affected the diagnosis of urologic cancers.
Presented by André Deschamps, MD
( André Deschamps, MD, presented a study assessing the quality of life of patients after being treated for prostate cancer. The study involved a 20-minute online survey intended for patients with prostate cancer who received treatment in Europe. It is an observational one-arm study, aiming to examine the quality of life of prostate cancer patients in Europe.
Presented by Elizabeth Wulff-Burchfield, MD
( Elizabeth Wulff-Burchfield, MD, is a medical oncologist specializing in palliative care. At the 2020 Society of Urologic Oncology Virtual Webcast, she discussed supportive and palliative care for urologists.
Presented by Kathryn Hacker Gessner, MD, Ph.D.
Washington, DC ( There is an increasing recognition that postoperative opioid prescriptions are contributing to the opioid crisis in the United States. This is in part due to the diversion of excess opioid medications,
Presented by Neeraj Agarwal, MD
Barcelona, Spain ( Androgen deprivation therapy (ADT) has long been considered the standard of care for patients with metastatic prostate cancer, however recent studies have shown improved survival outcomes by adding additional agents.
Presented by Henrik Gronberg, MD, PhD
Barcelona, Spain ( At the prostate cancer poster discussion at ESMO 2019, Dr. Henrik Gronberg provided a discussion of three important abstracts: the updated STAMPEDE “M1|RT Comparison”, as well as patient reported outcomes from both ENZAMET and TITAN.
Presented by Sumanta K. Pal, MD
Chicago, IL ( The landscape of systemic therapy for metastatic renal cell carcinoma (mRCC) is rapidly changing. Beyond the addition of immune checkpoint inhibitor combinations (nivo/ipi), additional TKI’s (cabozantinib),

email news signup